The Book of Topical Ingredients

Full Spectrum CBD extract contains CBD alongside a full complement of minor cannabinoids (CBG, CBC, CBN, CBDV), terpenes, flavonoids, and trace THC (<0.3%). These compounds work synergistically through the Entourage Effect — each component modulates the activity of the others, producing a broader and more sustained receptor engagement than any single compound alone. CBD Isolate is 99%+ pure CBD with all other compounds removed. In topical applications, Full Spectrum formulations generally demonstrate broader receptor coverage (CB1, CB2, TRPV1, TRPM8, PPARγ) compared to isolate-only products. All Kannaco topicals use Full Spectrum extract.

CBD and CBG have complementary but distinct receptor profiles. CBD primarily modulates CB2 receptors (anti-inflammatory) and TRPV1 (pain signaling), while CBG has higher affinity for CB1 receptors in peripheral tissue, α2-adrenoceptors (muscle relaxation), and demonstrates potent inhibition of anandamide reuptake. The 1:1 ratio in Pro Cream and Pro Roll-On is designed to provide simultaneous engagement of both CB1 and CB2 peripheral pathways, as well as TRPV1 and α2-adrenoceptors — a broader receptor coverage than CBD alone. This is particularly relevant for musculoskeletal applications where both inflammatory and neurogenic components are present.

Arnica Montana flower extract contains helenalin and dihydrohelenalin sesquiterpene lactones, which inhibit NF-κB signaling — a key transcription factor in the inflammatory cascade. This mechanism is distinct from cannabinoid receptor pathways, making arnica a complementary anti-inflammatory ingredient rather than a redundant one. Arnica also contains thymol (antiseptic), flavonoids, and carotenoids. It has a long history of use in sports medicine and physical therapy for bruising, muscle soreness, and joint discomfort. Topical arnica is generally well-tolerated; it is contraindicated on broken skin or open wounds.

No — menthol and cannabinoids act on different receptors and the interaction is additive rather than competitive. Menthol is a TRPM8 agonist (the "cold" receptor) and also a mild TRPV1 antagonist at low concentrations — meaning it can reduce heat-pain signaling while simultaneously activating the cooling pathway. CBD is a TRPV1 agonist at higher concentrations (desensitizing the receptor over time) and a CB2 agonist. These mechanisms are complementary: menthol provides immediate sensory cooling and TRPV1 modulation, while CBD provides sustained CB2-mediated anti-inflammatory activity. Menthol also functions as a penetration enhancer, increasing the flux of co-applied compounds through the stratum corneum.

Methylsulfonylmethane (MSM) is an organosulfur compound that serves two functions in topical formulations: (1) it is a penetration enhancer — MSM disrupts the ordered lipid structure of the stratum corneum, increasing the permeability of co-applied compounds including cannabinoids; and (2) it has independent anti-inflammatory activity, inhibiting NF-κB and reducing levels of IL-1β, IL-6, and TNF-α in preclinical models. MSM is also a bioavailable source of sulfur, which is required for collagen synthesis and glutathione production. It is generally well-tolerated topically and is commonly used in sports recovery formulations.

Shea butter (Butyrospermum Parkii) is derived from the shea tree nut and may be a concern for patients with tree nut allergies. However, highly refined shea butter typically has very low protein content, and the proteins responsible for IgE-mediated nut allergies are generally not present in refined cosmetic-grade shea. That said, patients with known tree nut allergies should consult their allergist before using Pro Cream, which contains shea butter. The CBD Cooling Cream and Pro Roll-On do not contain shea butter. MCT oil (coconut-derived) may also be relevant for patients with coconut allergies, though coconut is classified as a tree nut by the FDA and cross-reactivity with other tree nuts is generally low.

The risk of a positive drug test from topical CBD application is very low but cannot be categorically excluded. Standard urine drug screens test for THC-COOH, a metabolite of THC. Topical application of Full Spectrum CBD products results in negligible systemic absorption — the cannabinoids remain localized in the dermis and do not reach the bloodstream in meaningful quantities. However, Kannaco products contain trace THC (<0.3% by dry weight, per federal hemp regulations). In theory, very heavy use of large amounts of topical Full Spectrum CBD could result in detectable THC-COOH in urine, though this has not been documented in the published literature. For patients subject to drug testing in high-stakes environments (professional athletes, DOT employees, military), the conservative recommendation is to use a CBD Isolate-based product or to consult with the testing authority.

Aloe Barbadensis Leaf Juice serves as the aqueous base of all three Kannaco formulations, replacing plain water. This is a meaningful formulation decision: aloe provides acemannan (a polysaccharide with humectant and skin-soothing properties), anthraquinones (mild analgesic), and gibberellins (growth factor activity supporting wound healing). As the first ingredient listed, aloe constitutes the largest percentage of the formulation by weight. Using aloe as the base rather than water increases the functional ingredient load of the product and contributes to the smooth, non-greasy application texture.

Kannaco does not recommend use of any CBD-containing product during pregnancy or breastfeeding. The FDA has advised against CBD use during pregnancy and lactation due to insufficient safety data. While topical application results in minimal systemic absorption, the precautionary principle applies given the potential for fetal or neonatal exposure. Additionally, camphor (present in the CBD Cooling Cream and Pro Roll-On) is contraindicated during pregnancy at higher concentrations. Practitioners should advise pregnant and breastfeeding patients to avoid these products and consult their OB/GYN.

Document topical CBD recommendations as you would any OTC topical recommendation. Note the product name, concentration (e.g., "Kannaco CBD Cooling Cream, 2,000mg Full Spectrum CBD per 2 fl oz"), application site, frequency, and clinical rationale. Note any relevant contraindications reviewed (drug testing status, pregnancy, known allergies). Since CBD topicals are OTC cosmetic products and not prescription drugs, they do not require a prescription or DEA registration to recommend. However, maintaining documentation of your clinical reasoning protects you in the event of a patient complaint or audit. Some practitioners include a brief informed consent note acknowledging the patient understands this is an OTC supplement, not an FDA-approved drug.